Paratek Beats Suit Alleging $462M Sale Built On D&O Interests
A Delaware vice chancellor on Wednesday tossed investor challenges to Paratek Pharmaceuticals' $462 million sale to Gurnet Point Capital and Novo Holdings, saying it was not reasonably conceivable that directors and...To view the full article, register now.
Already a subscriber? Click here to view full article